本文へスキップ

(社)東京血液疾患研究所(MRC JAPAN)は、国際MDS財団に認定されたCenter of Excellenceです。

MRC JAPANは世界最先端の
骨髄異形成症候群(MDS)の研究機関です。

論文(欧文原著)Papers&Presentation

元に戻る

1, 欧文原著

論文


2012年

1. Tamura H, Ishibashi M, Yamashita T, Tanosaki S, Okuyama N, Kondo A, Hyodo H, Shinya E, Takahashi H, Dong H, Tamada K, Chen L, Dan K, Ogata K. Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma. Leukemia (in press)

2. Ogata K, Kakumoto K, Matsuda A, Tohyama K, Tamura H, Ueda Y, Kurokawa M, Takeuchi J, Shibayama H, Emi N, Motoji T, Miyazaki Y, Tamaki H, Mitani K, Naoe T, Sugiyama H, Takaku F. Differences in blast immunophenotypes among disease types in myelodysplastic syndromes: a multicenter validation study. Leuk Res 36, 1229–1236, 2012

3. Della Porta MG, Picone C, Pascutto C, Malcovati L, Tamura H, Handa H, Czader M, Freeman S, Vyas P, Porwit A, Saft L, Westers TM, Alhan C, Cali C, Van de Loosdrecht AA, Ogata K. Multicentre validation of a reproducible flow cytometric score for the diagnosis of low-risk myelodysplastic syndromes: results of a European LeukemiaNET study. Haematol-Hematol J (Haematologica) 97, 1209-1217, 2012

4. Westers TM, Ireland R, Kern W, Alhan C, Balleisen JS, Bettelheim P, Burbury K, Cullen M, Cutler JA, Della Porta MG, Dräger AM, Feuillard J, Font P, Germing U, Haase D, Johansson U, Kordasti S, Loken MR, Malcovati L, Te Marvelde JG, Matarraz S, Milne T, Moshaver B, Mufti GJ, Ogata K, Orfao A, Porwit A, Psarra K, Richards SJ, Subirá D, Tindell V, Vallespi T, Valent P, van der Velden VH, de Witte TM, Wells DA, Zettl F, Béné MC, van de Loosdrecht AA. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet working group. Leukemia 26, 1730-41, 2012

2011年以前
2011年
1 Ishibashi M, Tamura H, Ogata K.
Disease progression mechanism in myelodysplastic  yndromes: insight into the role of the microenvironment. Leuk Res 35, 1449-52, 2011

2010年
1 Kondo A, Yamashita T, Tamura H, Zhao W, Tsuji T, Shimizu M, Shinya E, Takahashi H, Tamada K, Chen L, Dan K, Ogata K.
Interferon- g and tumor necrosis factor-a induce an immunoinhibitory molecule, B7-H1, via nuclear factor k B activation in blasts in myelodysplastic syndromes.Blood 116, 1124-1131, 2010
2 Tamura H, Dan K, Yokose N, Iwakiri R, Ohta M, Sakamaki H, Tohyama K, Kondo A, Hyodo H, Nakamura K, Yamashita T, Elisseeva OA, Oka Y, Oji Y, Sugiyama H, Ogata K
Prognostic significance of WT1 mRNA and anti-WT1 antibody levels in peripheral blood in patients with myelodysplastic syndromes. Leuk Res 34, 986-90, 2010

2009年
1 Ogata K, Della Porta MG, Malcovati L, Picone C, Yokose N, Matsuda A, Yamashita T, Tamura H, Tsukada J, Dan K
Diagnostic utility of flow cytometry in low-risk myelodysplastic syndromes: a prospective validation study. Haematol-Hematol J (Haematologica) 94, 1066-74, 2009
2 Satoh C, Tamura H, Yamashita T, Tsuji T, Dan K, Ogata K.
Aggressive characteristics of myeloblasts expressing CD7 in myelodysplastic syndromes. Leuk Res 33, 326-331, 2009
3 Yamashita T, Tamura H, Satoh C, Shinya E, Takahashi H, Kondo A, Chen L, Tsuji T, Dan K, Ogata K.
Functional B7.2 and B7-H2 molecules on myeloma cells are associated with a growth advantage. Clin Cancer Res 15, 770-7. 2009
4 van de Loosdrecht AA., Alhan C, B?n? MC, Della Porta MG, Dr?ger AM, Feuillard J, Font P, Germing U, Haase D, Homburg CH, Ireland R, Jansen JH, Kern W, Malcovati L, Marvelde JG, Mufti GJ, Ogata K, Orfao A, Ossenkoppele GJ, Porwit A, Preijers FW, Richards SJ, Schuurhuis1 GJ, Subir? D, Valent P, Vivan der Velden VHJ, Vyas P, Westra1 AH, de Witte TM, Wells DA, Loken M, Westers TM.
Standardization of flow cytometry in myelodysplastic syndromes: Report from the first ELNet working conference on flow cytometry in MDS. Haematol-Hematol J (Haematologica) 94, 1124-1134, 2009

2008年
1 Satoh C, Dan K, Yamashita T, Jo R, Tamura H, Ogata K.
Flow cytometric parameters with little interexaminer variability for diagnosing low-grade myelodysplastic syndromes. Leuk Res 32, 699-707, 2008
2 Loken MR, van de Loosdrecht A, Ogata K, Orfao A, Wells DA.
Flow cytometry in myelodysplastic syndromes: report from a working conference. Leuk Res 32, 5-17, 2008

2007年
1 Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, Haferlach T, Haase D, Kolb HJ, Krieger O, Loken M, van de Loosdrecht A, Ogata K, Orfao A, Pfeilst?cker M, R?ter B, Sperr WR, Stauder R, Wells DA.
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res 31, 727-736, 2007
2 Shioi Y, Tamura H, Yokose N, Satoh C, Dan K, Ogata K.
Increased apoptosis of circulating T cells in myelodysplastic syndromes. Leuk Res 31, 1641-1648, 2007

2006年
1 Ogata K, Kishikawa Y, Satoh C, Tamura H, Dan K, Hayashi A.
Diagnostic application of flow cytometric characteristics of CD34+ cells in low-grade myelodysplastic syndromes. Blood 108, 1037-1044, 2006
2 Satoh C, Ogata K.
Hypothesis: Myeloid-restricted hematopoietic stem cells with self-renewal capacity may be the transformation site in acute myeloid leukemia. Leuk Res 30, 491-495, 2006

2005年
1 Wu F, Oka Y, Tsuboi A, Elisseeva OA, Ogata K, Nakajima H, Fujiki F, Masuda T, Murakami M, Yoshihara S, Ikegame K, Hosen N, Kawakami M, Nakagawa M, Kubota T, Soma T, Yamagami T, Tsukaguchi M, Ogawa H, Oji Y, Hamaoka T, Kawase I, Sugiyama H.
Th1-biased humoral immuneresponses against Wilms tumor gene WT1 product in the patients with hematopoietic malignancies. Leukemia 19, 268-274, 2005
2 Tamura H, Dan K, Tamada K, Nakamura K, Shioi Y, Hyodo H, Wang SD, Dong H, Chen L, Ogata K.
Expression of functional B7-H2 and B7.2 costimulatory molecules and their prognostic implications in de novo acute myeloid leukemia. Clin Cancer Res 11, 5708-5717, 2005
3 Suzuki R, Nakamura S, Suzumiya J, Ichimura K, Ichikawa M, Ogata K, Kura Y, Aikawa K, Teshima H, Sako M, Kojima H, Nishio M, Yoshino T, Sugimori H, Kawa K, Oshimi K.
Blastic natural killer cell lymphoma/leukemia (CD56-positive blastic tumor). Cancer 104, 1022-1031, 2005
4 Ogata K, Satoh C, Tachibana M, Hyodo H, Tamura H, Dan K, Kimura T, Sonoda Y, Tsuji T.
Identification and hematopoietic potential of CD45- clonal cells with very immature phenotype (CD45-CD34-CD38-Lin-) in patients with myelodysplastic syndromes. Stem Cells 23, 619-630, 2005

2004年
1 Ogata K, Satoh C, Hyodo H, Tamura H, Dan K, Yoshida Y.
Association between phenotypic features of blasts and the blast percentage in bone marrow of patients with myelodysplastic syndromes. Leuk Res 28, 1171-1175, 2004

2003年
1 Hyodo H, Ogata K, Tachibana M, Dan K.
Characterization of blasts in clinical samples containing few blasts. Int J Hematol 77, 376-382, 2003

2002年
1 Ogata K, Nakamura K, Yokose N, Tamura H, Tachibana M, Taniguchi O, Iwakiri R, Hayashi T, Sakamaki H, Murai Y, Tohyama K, Tomoyasu S, Nonaka Y, Mori M, Dan K, Yoshida Y.
Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood 100, 3887-3896, 2002
2 Tsunetsugu-Yokota Y, Tamura H, Tachibana M, Ogata K, Honda M, Takemori T.
Selective expansion of perforin-positive CD8+ T cells by immature dendritic cells infected with live Bacillus Calmette-Guerin mycobacteria. J Leukoc Biol 72, 115-124, 2002
3 Elisseeva OA, Oka Y, Tsuboi A, Ogata K, Wu F, Kim EH, Soma T, Tamaki H, Kawakami M, Oji Y, Hosen N, Kubota T, Nakagawa M, Yamagami T, Hiraoka A, Tsukaguchi M, Udaka K, Ogawa H, Kishimoto T, Nomura T, Sugiyama H.
Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies. Blood 99, 3272-3279, 2002

2001年
1 Ogata K, Yokose N, Shioi Y, Ishida Y, Tomiyama J, Hamaguchi H, Yagasaki F, Bessyo M, Sakamaki H, Dan K, Kuriya S.
Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia. Br J Haematol 115, 612-615, 2001
2 Ogata K.
A simple centrifugation method for harvesting myeloblasts. Int J Hematol 74, 272-276, 2001
3 Ogata K, An E, Shioi Y, Nakamura K, Luo S, Yokose N, Minami S, Dan K.
Association between natural killer cell activity and infection in immunologically normal elderly people. Clin Exp Immunol 124, 392-397, 2001

2000年
1 Kamikubo KH, Ogata K, An E, Dan K.
Low proportion of G0-phase cells during induction chemotherapy correlates with subsequent remission in acute myeloid leukemia. Int J Hematol 71, 249-255, 2000
2 Nakamura K, Ogata K, An E, Dan K.
Flow cytometric assessment of CD15+CD117+ cells for the detection of minimal residual disease in adult acute myeloid leukaemia. Br J Haematol 108, 710-716, 2000
3 Luo SS, Ogata K, Yokose N, Kato T, Dan K.
Effect of thrombopoietin on proliferation of blasts from patients with myelodysplastic syndromes. Stem Cells 18, 112-119, 2000

1998年
1 Tamura H, Ogata K, Luo S, Nakamura K, Yokose N, Dan K, Tohyama K, Yoshida Y, Hamaguchi H, Sakamaki H, Kuwaki T, Tahara T, Kato T, Nomura T.
Plasma thrombopoietin (TPO) levels and expression of TPO receptor on platelets in patients with myelodysplastic syndromes. Br J Haematol 103, 778-784, 1998
2 Ogata K, An E, Kamikubo K, Yokose N, Tamura H, Yamada T, Gomi S, Dan K, Nomura T.
Repeated cycles of G-CSF-combined postremission chemotherapy for acute myeloid leukemia in a first complete remission: a pilot study. Stem Cells 16, 280-287, 1998
3 Yokose N, Ogata K, Tamura H, An E, Nakamura K, Kamikubo K, Kudoh S, Dan K, Nomura T.
Pulmonary toxicity after granulocyte colony-stimulating factor-combined chemotherapy for non-Hodgkin’s lymphoma. Br J Cancer 77, 2286-2290, 1998

1997年
1 Tamura H, Ogata K, Dan K, Nomura T.
Rationale and hematologic target points in response-oriented individualized induction chemotherapy for acute myeloid leukemia. Int J Hematol 66, 325-334, 1997
2 Ogata K, Yokose N, Tamura H, An E, Nakamura K, Dan K, Nomura T.
Natural killer cells in thelate decades of human life. Clin Immunol Immunopathol 84, 269-275, 1997
3 Ogata K, An E, Kamikubo K, Tamura H, Yokose N, Dan K, Nomura T.
Cell cycle modulation by hematopoietic growth factors in myelodysplastic syndromes: analysis by three-color flow cytometry. Exp Hematol 25, 8-18, 1997

1996年
1 Ogata K, Tamura H, Yokose N, Dan K, Nomura T.
CD4 lymphopenia and risk of infection in immunogerontologically healthy elderly people. Lancet 347(9012), 1408, 1996
2 Ogata K, Yokose N, An E, Kamikubo K, Tamura H, Dan K, Sakamaki H, Onozawa Y, Hamaguchi H, Nomura T.
Plasma soluble interleukin-2 receptor level in patients with primary myelodysplastic syndromes: a relationship with disease subtype and clinical outcome. Br J Haematol 93, 45-52, 1996

1995年
1 Dan K, Gomi S, Inokuchi K, Ogata K, Yamada T, Ohki I, Hasegawa S, Nomura T.
Effects of interleukin-1 and tumor necrosis factor on megakaryocytopoiesis: mechanism of reactive thrombocytosis. Acta Haematol 93, 67-72, 1995
2 Ogata K, Tamura H, Yokose N, An E, Dan K, Hamaguchi H, Sakamaki H, Onozawa Y, Clark SC, Nomura T.
Effects of interleukin-12 on natural killer cell cytotoxicity and the production of interferon-gamma and tumour necrosis factor-alpha in patients with myelodysplastic syndromes. Br J Haematol 90, 15-21, 1995

1994年
1 Ogata K, Fujii H, Yokose N, An E, Tamura H, Kamikubo K, Dan K, Hamaguchi H, Sakamaki H, Onozawa Y, Nomura T.
Defective natural killer (NK) cell-mediated cytotoxicity does not imply clonal involvement of NK cells in myelodysplastic syndromes. Br J Haematol 87, 396-398, 1994
2 Ogata K, Yokose N, Ito T, An E, Tamura H, Dan K, Hamaguchi H, Sakamaki H, Onozawa Y, Nomura T.
Assessment of therapeutic potential of interleukin 2 for myelodysplastic syndromes.Br J Haematol 86, 562-567, 1994
3 Yokose N, Ogata K, Ito T, An E, Tamura H, Dan K, Hamaguchi H, Sakamaki H, Onozawa Y, Nomura T.
Elevated plasma soluble interleukin 2 receptor level correlates with defective natural killer and CD8+ T-cells in myelodysplastic syndromes. Leuk Res 18, 777-782, 1994
4 Yokose N, Ogata K, Dan K, Nomura T.
Aplastic anemia with circulating erythroblasts. Int J Hematol 60, 111-117, 1994
5 An E, Ogata K, Kuriya S, Nomura T.
Interleukin-6 and erythropoietin act as direct potentiators and inducers of in vitro cytoplasmic process formation on purified mouse megakaryocytes. Exp Hematol 22, 149-156, 1994

1993年
1 Ogata K, Yokose N, Ito T, An E, Dan K, Nomura
Effects of interleukin 2 on myelodysplastic syndromes. Leuk Res 17, 137-42, 1993
2 Kuriya S, Ogata K, An E, Hamaguchi H, Yokose N, Anzai Y, Nomura T.
A novel megakaryocyte potentiator produced by MC-1 human lung cancer cell line. Pathobiology 61, 256-267, 1993
3 Yokose N, Ogata K, Ito T, Miyake K, An E, Inokuchi K, Yamada T, Gomi S, Tanabe Y, Ohki I, Kuwabara T, Hasegawa S, Shinohara T, Dan K, Nomura T.
Chemotherapy for minimally differentiated acute myeloid leukemia (AML-M0). A report on five cases and review of the literature. Ann Hematol 66, 67-70, 1993
4 Dan K, An E, Futaki M, Inokuchi K, Gomi S, Yamada T, Ogata K, Tanabe Y, Ohki I, Shinohara T, Nomura T.
Megakaryocyte, erythroid and granulocyte-macrophage colony formation in myelodysplastic syndromes. Acta Haematol 89, 113-118, 1993

1992年
1 Ogata K, Erickson-Miller CL, Nomura T, Abe K, Zhang Z, Murphy MJ Jr.
Effects of recombinant cytokines on murine megakaryocyte colony formation in a serum-free fibrin clot culture system. Pathobiology 60, 143-148, 1992
2 Ogata K, Yamada T, Ito T, Gomi S, Tanabe Y, Ohki I, Dan K, Nomura T.
Low-dose etoposide: a potential therapy for myelodysplastic syndromes. Br J Haematol 82, 354-357, 1992

1991年
1 Murphy MJ Jr, Ogata K.
In vitro cloning of murine megakaryocyte progenitors (CFU-Meg). J Tissue Culture Methods (現在は “Cytotechnology” へ名称変更) 13, 83-88, 1991

1990年
1 Ogata K, Zhang ZG, Abe K, Murphy MJ Jr.
Partial purification and characterization of human megakaryocyte colony-stimulating factor (Meg-CSF). Int J Cell Cloning (現Stem Cells) 8 Suppl 1, 103-120, 1990
2 Kuriya S, Ogata K, Yamada T, Gomi S, Nomura T.
Stages of differentiation in mouse megakaryocyte progenitor cells (CFU-Meg). Exp Hem Three atol 18, 416-420, 1990
3 Ogata K, Dan K, Kuriya S, Nomura T.
Anti-thoracic duct lymphocyte globulin stimulates human megakaryocytopoiesis in vitro. Blut 60, 202-205, 1990

1989年
1 Ogata K, Kuriya S, Dan K, Nomura T.
Partial purification of human urinary megakaryocyte colony-stimulating factor.Exp Cell Biol (現Pathobiology) 57, 19-26, 1989
2 Kuriya S, Tajika K, Ogata K, Nomura T.
A simple method for ultrastructural observation of in vitro hematopoietic and leukemic colonies formed in fibrin- and plasma-clots. Acta Haematol Jpn (現Int J Hematol) 52, 18-24, 1989

1986年
1 Ogata K, Ito T, Okazaki T, Dan K, Nomura T, Nozawa Y, Kajita A.
Hemoglobin Sendagi (beta 42 Phe→Val): a new unstable hemoglobin variant having an amino acid substitution at CD1 of the beta-chain. Hemoglobin 10, 469-481, 1986

  

Supported by

Supported by

(社)東京血液疾患研究所
(MRC JAPAN)

〒182-0001
東京都調布市緑ヶ丘1-45-46
        クレナイビル3F
TEL 03-6750-1017
FAX 03-6750-1013

E-mail : info@MRCJAPAN.com

9、